In addition, while the BRD4 inhibitors PLX2853 and INCB054329 show synergistic anticancer effects when combined with the BCL2 inhibitor Venetoclax in mouse models of diffuse large B-cell lymphoma and acute myeloid leukemia, ABBV-744 also exerts synergistic anticancer effects with Venetoclax in mouse models of acute myeloid leukemia (Table 2) [56, 57]. This evidence concerns the gene BCL2 and acute myeloid leukemia.